Genitourinary Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

The Market is Segmented by Disease Type, Drug Type, and Geography

Market Snapshot

Picture1 Genitourinary Drugs Market
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

2.6 %

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The rise in the incidence of genitourinary diseases and infections has led to the growth of the genitourinary drugs market, globally. Rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments in R&D activities in developing novel molecules for the treatment of genitourinary diseases, and the increasing number of pipeline drugs are also expected to drive the market, during the forecast period. However, an increasing number of counterfeit drugs and lack of awareness about the infections and drugs for the treatment are going to restrain the market for genitourinary drugs.

Scope of the Report

Genitourinary tract agents are medicines, which are used to treat conditions of the reproductive organs and excretory system or urinary tract. The term "genitourinary" actually refers to two different systems. Urinary refers to the system responsible for removal of nitrogenous waste products of metabolism from the bloodstream, disposal of concentrated wastes (urine), and also water conservation. Genito refers to the genital organs and the reproductive system, which is responsible for the production of succeeding generations for the perpetuation of the species. The genitourinary (GU) system may be affected by congenital abnormalities, inflammation, infection, other body systems or diseases of the kidneys.

By Disease Type
Erectile dysfunction
Gonorrhoea
Genital Herpes
Urinary Tract Infections
Urinary Incontinence
Glomerulonephritis
Chronic renal failure
Other Product Types
By Drug Type
Harmonal Therapy
Impotence Agents
Uterine Relaxants
Urinary Antispasmodics
Urinary pH Modifiers
Uterine Stimulants
Miscellaneous Genitourinary Tract Agents
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Urinary Tract Infections to dominate the Global Genitourinary Drugs Market

As there is an increase in the incidence of urinary tract infections, the demand for drugs increases, which, in turn, is driving the global urinary tract infection therapeutics market. Furthermore, the launch of combination drugs, development, and approval of new drugs, which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection segment in the global genitourinary drugs market. For instance, in August 2017, FDA approved Vabomere for adults. Vabomere is an antibacterial drug, which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam. In December 2017, the FDA accepted the review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI, including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) for June 2018.

Picture2 Genitourinary Drugs Market

To understand key trends, Download Sample Report

Asia Pacific is expected to be the fastest growing region

Asia is expected to experience a high growth rate in the genitourinary drugs market in the next few years, due to rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases, increasing awareness about genitourinary diseases, rise in health care expenditure, and developing health care infrastructure in the region. Growing demographics and economies in the developing countries, such as India and China, are expected to lead to the rise of the genitourinary drugs market in the Asia-Pacific region.

Picture3 Genitourinary Drugs Market

To understand geography trends, Download Sample Report

Competitive Landscape

The global genitourinary drugs market displays high competition among market players. Major market players are investing high capitals on R&D and generating many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions to strengthen their market position in the global genitourinary drugs market. For instance, in September 2018: TherapeuticsMD Inc. launched Imvexxy (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia. Major players in the global genitourinary drugs market include Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline, Achaogen Inc., Melinta Therapeutics Inc., Wellstat Therapeutics Corporation, Allergan Merck & Co. Inc., Novartis AG, and Pfizer among others.

Major Players

  1. Allergan
  2. Bristol-Myers Squibb Co.
  3. Melinta Therapeutics Inc.
  4. Achaogen Inc.
  5. Wellstat Therapeutics Corporation

* Complete list of players covered available in the table of contents below

Picture4 Genitourinary Drugs Market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Genitourinary Disorders

      2. 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure

      3. 4.2.3 Increasing Pipeline Products

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Therapy Compliance

      2. 4.3.2 Increasing Advent of Counterfeit Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Erectile dysfunction

      2. 5.1.2 Gonorrhoea

      3. 5.1.3 Genital Herpes

      4. 5.1.4 Urinary Tract Infections

      5. 5.1.5 Urinary Incontinence

      6. 5.1.6 Glomerulonephritis

      7. 5.1.7 Chronic renal failure

      8. 5.1.8 Other Product Types

    2. 5.2 By Drug Type

      1. 5.2.1 Harmonal Therapy

      2. 5.2.2 Impotence Agents

      3. 5.2.3 Uterine Relaxants

      4. 5.2.4 Urinary Antispasmodics

      5. 5.2.5 Urinary pH Modifiers

      6. 5.2.6 Uterine Stimulants

      7. 5.2.7 Miscellaneous Genitourinary Tract Agents

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb Co.

      2. 6.1.2 Eli Lilly and Company

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Achaogen Inc.

      5. 6.1.5 Melinta Therapeutics Inc.

      6. 6.1.6 Wellstat Therapeutics Corporation

      7. 6.1.7 Allergan

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Novartis AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information